What is the Fiscal Year for Altimmune?
Date: November 13, 2026
Altimmune's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Morristown, New Jersey
Industry
Biotechnology Research
Stock Symbol
ALT
Website
https://altimmune.comDescription
Altimmune is a late clinical-stage biopharmaceutical company developing therapies to improve the lives of people living with serious liver diseases. Our lead program is a differentiated dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio, currently in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). #ClinicalResearch #LiverCare #BioResearch
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Altimmune and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.